gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study

E. Van Cutsem; T. Yoshino; H. J. Lenz; S. Lonardi; A. Falcone; M. L. Limon; M. P. Saunders; A. Sobrero; E. Maiello; Y. S. Park; R. Ferreiro Monteagudo; Y. S. Hong; J. Tomasek; H. Taniguchi; F. Ciardiello; J. Hocke; Z. Oum'hamed; S. Vlassak; M. Studeny; J. Tabernero

doi:10.1093/annonc/mdw435.12

gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study

E. Van Cutsem, T. Yoshino, H. J. Lenz, S. Lonardi, A. Falcone, M. L. Limon, M. P. Saunders, A. Sobrero, E. Maiello, Y. S. Park, R. Ferreiro Monteagudo, Y. S. Hong, J. Tomasek, H. Taniguchi, F. Ciardiello, J. Hocke, Z. Oum'hamed, S. Vlassak, M. Studeny, J. Tabernero

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	vi559
Journal	Annals of Oncology
Volume	27
DOIs	https://doi.org/10.1093/annonc/mdw435.12
Publication status	Published - Oct 1 2016

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdw435.12

Cite this

Van Cutsem, E., Yoshino, T., Lenz, H. J., Lonardi, S., Falcone, A., Limon, M. L., Saunders, M. P., Sobrero, A., Maiello, E., Park, Y. S., Monteagudo, R. F., Hong, Y. S., Tomasek, J., Taniguchi, H., Ciardiello, F., Hocke, J., Oum'hamed, Z., Vlassak, S., Studeny, M., & Tabernero, J. (2016). gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study. Annals of Oncology, 27, vi559. https://doi.org/10.1093/annonc/mdw435.12

gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies : Results of the phase III LUME-colon 1 study. / Van Cutsem, E.; Yoshino, T.; Lenz, H. J.; Lonardi, S.; Falcone, A.; Limon, M. L.; Saunders, M. P.; Sobrero, A.; Maiello, E.; Park, Y. S.; Monteagudo, R. Ferreiro; Hong, Y. S.; Tomasek, J.; Taniguchi, H.; Ciardiello, F.; Hocke, J.; Oum'hamed, Z.; Vlassak, S.; Studeny, M.; Tabernero, J.

In: Annals of Oncology, Vol. 27, 01.10.2016, p. vi559.

Research output: Contribution to journal › Article › peer-review

Van Cutsem, E, Yoshino, T, Lenz, HJ, Lonardi, S , Falcone, A, Limon, ML, Saunders, MP, Sobrero, A , Maiello, E, Park, YS, Monteagudo, RF, Hong, YS, Tomasek, J, Taniguchi, H, Ciardiello, F, Hocke, J, Oum'hamed, Z, Vlassak, S, Studeny, M & Tabernero, J 2016, 'gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study', Annals of Oncology, vol. 27, pp. vi559. https://doi.org/10.1093/annonc/mdw435.12

Van Cutsem E, Yoshino T, Lenz HJ, Lonardi S , Falcone A, Limon ML et al. gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study. Annals of Oncology. 2016 Oct 1;27:vi559. https://doi.org/10.1093/annonc/mdw435.12

Van Cutsem, E. ; Yoshino, T. ; Lenz, H. J. ; Lonardi, S. ; Falcone, A. ; Limon, M. L. ; Saunders, M. P. ; Sobrero, A. ; Maiello, E. ; Park, Y. S. ; Monteagudo, R. Ferreiro ; Hong, Y. S. ; Tomasek, J. ; Taniguchi, H. ; Ciardiello, F. ; Hocke, J. ; Oum'hamed, Z. ; Vlassak, S. ; Studeny, M. ; Tabernero, J. / gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies : Results of the phase III LUME-colon 1 study. In: Annals of Oncology. 2016 ; Vol. 27. pp. vi559.

@article{8be8600913644e05acb5b0ec82b84ed5,

title = "gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study",

author = "{Van Cutsem}, E. and T. Yoshino and Lenz, {H. J.} and S. Lonardi and A. Falcone and Limon, {M. L.} and Saunders, {M. P.} and A. Sobrero and E. Maiello and Park, {Y. S.} and Monteagudo, {R. Ferreiro} and Hong, {Y. S.} and J. Tomasek and H. Taniguchi and F. Ciardiello and J. Hocke and Z. Oum'hamed and S. Vlassak and M. Studeny and J. Tabernero",

year = "2016",

month = oct,

day = "1",

doi = "10.1093/annonc/mdw435.12",

language = "English",

volume = "27",

pages = "vi559",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

}

TY - JOUR

T1 - gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies

T2 - Results of the phase III LUME-colon 1 study

AU - Van Cutsem, E.

AU - Yoshino, T.

AU - Lenz, H. J.

AU - Lonardi, S.

AU - Falcone, A.

AU - Limon, M. L.

AU - Saunders, M. P.

AU - Sobrero, A.

AU - Maiello, E.

AU - Park, Y. S.

AU - Monteagudo, R. Ferreiro

AU - Hong, Y. S.

AU - Tomasek, J.

AU - Taniguchi, H.

AU - Ciardiello, F.

AU - Hocke, J.

AU - Oum'hamed, Z.

AU - Vlassak, S.

AU - Studeny, M.

AU - Tabernero, J.

PY - 2016/10/1

Y1 - 2016/10/1

UR - http://www.scopus.com/inward/record.url?scp=85024892790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024892790&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdw435.12

DO - 10.1093/annonc/mdw435.12

M3 - Article

VL - 27

SP - vi559

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -